Information Provided By:
Fly News Breaks for February 16, 2017
CHE
Feb 16, 2017 | 08:07 EDT
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $180 from $175 after the company reported in-line Q4 results and "strong" guidance. The analyst reiterates an Outperform rating on the shares as Chemed operates in two "solid businesses" with continued stable growth prospects.
News For CHE From the Last 2 Days
There are no results for your query CHE